1. Metabolic Enzyme/Protease
  2. Endogenous Metabolite
  3. β-Nicotinamide mononucleotide

β-Nicotinamide mononucleotide (Synonyms: β-NM; NMN)

Cat. No.: HY-F0004 Purity: 99.93%
Handling Instructions

β-nicotinamide mononucleotide (β-NM) is a product of the nicotinamide phosphoribosyltransferase (NAMPT) reaction and a key NAD(+) intermediate. The pharmacological activities of β-nicotinamide mononucleotide include its role in cellular biochemical functions, cardioprotection, diabetes, Alzheimer's disease, and complications associated with obesity.

For research use only. We do not sell to patients.

β-Nicotinamide mononucleotide Chemical Structure

β-Nicotinamide mononucleotide Chemical Structure

CAS No. : 1094-61-7

Size Price Stock Quantity
Free Sample (0.5-1 mg)   Apply Now  
10 mM * 1 mL in Water USD 66 In-stock
Estimated Time of Arrival: December 31
10 mg USD 60 In-stock
Estimated Time of Arrival: December 31
50 mg USD 144 In-stock
Estimated Time of Arrival: December 31
100 mg USD 228 In-stock
Estimated Time of Arrival: December 31
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

Customer Review

Based on 2 publication(s) in Google Scholar

Top Publications Citing Use of Products
  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

β-nicotinamide mononucleotide (β-NM) is a product of the nicotinamide phosphoribosyltransferase (NAMPT) reaction and a key NAD(+) intermediate. The pharmacological activities of β-nicotinamide mononucleotide include its role in cellular biochemical functions, cardioprotection, diabetes, Alzheimer's disease, and complications associated with obesity[1].

IC50 & Target

Human Endogenous Metabolite

 

In Vitro

β-nicotinamide mononucleotide has several beneficial pharmacological activities. Mostly mediated by its involvement in NAD+ biosynthesis, the pharmacological activities of NMN include its role in cellular biochemical functions, cardioprotection, diabetes, Alzheimer's disease, and complications associated with obesity[1].
The intracellular NAD+ levels are significantly decreased by knockdown or knockout of Nampt (Nampt KD or Nampt KO) or treatment with Nampt inhibitor FK866, whereas NAD+ levels are dramatically increased by supplement of NAD+ precursors NAM or NMN (0.5–1 mM). NAD+ precursor NMN treatment inhibited CD8+ T cells activation and function[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

β-Nicotinamide mononucleotide (500 mg/kg; i.p.; 3 times per week for 7-10 week) prevents mtDNA damage and Dox-induced cardiac dysfunction[3].
Nampt KO markedly inhibits tumor progression, whereas Nampt metabolite β-Nicotinamide mononucleotide (300 mg/kg body weight; i.p.; once every two days for 2 weeks) significantly promotes tumor growth in C57BL/6 mice (bearing wildtype Hepa1-6 cells). The reduction and increase in NAD+ level of respective Nampt KO and β-Nicotinamide mononucleotide-treated tumors are confirmed[2].
β-nicotinamide mononucleotide ameliorates glucose intolerance by restoring NAD(+) levels in HFD-induced T2D mice. β-nicotinamide mononucleotide also enhances hepatic insulin sensitivity and restores gene expression related to oxidative stress, inflammatory response, and circadian rhythm, partly through SIRT1 activation[4].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: C57BL6 mice (p53−/− mice)[3]
Dosage: 500 mg/kg
Administration: I.p.; 3 times per week for 7-10 week
Result: Prevented the significant decline in cardiac function of Dox-treated p53−/− mice (study week 7 versus 10) along with rescuing the decreased mitochondrial respiration and tissue ATP depletion caused by Doxorubicin (Dox).
Molecular Weight

334.22

Formula

C₁₁H₁₅N₂O₈P

CAS No.

1094-61-7

SMILES

NC(C1=C[N+]([[email protected]@H]2O[[email protected]](COP(O)([O-])=O)[[email protected]@H](O)[[email protected]]2O)=CC=C1)=O

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Solvent & Solubility
In Vitro: 

H2O : 83.33 mg/mL (249.33 mM; Need ultrasonic)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 2.9920 mL 14.9602 mL 29.9204 mL
5 mM 0.5984 mL 2.9920 mL 5.9841 mL
10 mM 0.2992 mL 1.4960 mL 2.9920 mL
*Please refer to the solubility information to select the appropriate solvent.
In Vivo:
  • 1.

    Add each solvent one by one:  PBS

    Solubility: 100 mg/mL (299.20 mM); Clear solution; Need ultrasonic

*All of the co-solvents are provided by MCE.
References

Purity: 99.93%

  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.
  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2

Keywords:

β-Nicotinamide mononucleotideβ-NM NMNEndogenous MetabolitecardioprotectiondiabetesAlzheimer'sdiseaseobesitycancerNADintermediateInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

 

Salutation

Applicant Name *

 

Email address *

Phone number *

 

Organization name *

Department *

 

Requested quantity *

Country or Region *

     

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
β-Nicotinamide mononucleotide
Cat. No.:
HY-F0004
Quantity:
MCE Japan Authorized Agent: